The team of experts says the knowledge of the ‘good’ is important in the negative effects of the jab, because the vaccine was released from Brazil to Indonesia.
The COVID-19 vaccine developed by Sinovac Biotech in China is effective in preventing COVID-19 in older people over the age of 60 but some of the risk information for serious complications is missing, World Health Organization experts have found.
Independent experts on the WHO Strategic Advisory Group (SAGE) also reviewed CoronaVac’s Sinovac jab from 3 third clinical trials in China, Brazil, Indonesia, Turkey and Chile.
The review came shortly after the WHO SAGE experts expressed “very little confidence” in the information provided by Chinese drug manufacturers Sinopharm on its COVID-19 vaccine on the risk of further complications in some patients but with complete confidence in its ability to prevent the disease, according to a statement issued by Reuters news agency, which published the article Wednesday.
The Sinovac vaccine has been approved nationally by 32 states, and tested for 260 million, say SAGE experts.
“We are confident that the two levels of CoronaVac are effective in preventing PCR confirmation of COVID19 in adults (ages 18-59),” SAGE said in a review posted on the WHO website.
It also identified evidence gaps in central safety as well as safety and security for the elderly, those with the disease, and examined the risk factors associated with permitting subsequent protection.
The analysts said they had “low confidence” that the risk of serious adverse events was low in people aged 59 and younger, but “had low confidence” on the evidence that such a risk was also lower in adults above 60.
“We have little confidence in the evidence that the risk of serious complications in people with comorbidities or health is said to increase the risk of COVID-19 following one or two CoronaVac pathways is low,” he added.
A special panel of WHO experts is also reviewing Sinovac’s shot Wednesday to make possible emergency use of the WHO – which not only undermines the global use of the COVAX vaccine but also provides the world-class approval of a vaccine made in China.